Genfit SA

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

13 Nov 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2024 Financial Information

07 Nov 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

23 Sep 2024 00:30:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

19 Sep 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

26 Jul 2024 06:45:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

09 Jul 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

17 Jun 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

10 Jun 2024 16:22:00 By Nasdaq GlobeNewswire

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

29 May 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

22 May 2024 11:05:00 By Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2024 Financial Information

14 May 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

25 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

15 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

05 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

04 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2023

29 Feb 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces 2024 Financial Calendar  

15 Jan 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

11 Jan 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

08 Dec 2023 00:55:00 By Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 Dec 2023 04:15:01 By Nasdaq GlobeNewswire